Although WNK1–OSR1 inhibitors might cause an unwanted inflammation response and could be toxic, our combination therapy approach by integrating WNK1–OSR1 inhibitors with oligo-fucoidan (an anti-inflammatory agent) might serve as a promising novel anti-cancer therapeutic. This evidence concerns the gene OSR1 and cancer.